ALK and neoplasm: Major cooperative group trials differ in risk classification and treatment approach for patients with locoregional disease; additionally, patient outcomes vary depending on underlying tumor biology and genomics.34-36 Our data suggest that ALK aberrations in patients with nonmetastatic disease may be an adverse prognostic factor and treatment with an ALK inhibitor should be considered in future studies.